Ulcerative Colitis: Epidemiology Forecast to 2026

  • ID: 4601656
  • Report
  • 64 pages
  • GlobalData
1 of 3
Ulcerative Colitis: Epidemiology Forecast to 2026

Summary

Diagnosed incident cases of Ulcerative colitis (UC) are expected to increase from 94,303 cases in 2016 to 108,428 cases in 2026, at an Annual Growth Rate (AGR) of 1.5% in the 7MM. The US will have the highest number of diagnosed incident cases of Ulcerative colitis (UC) over the forecast period, while Spain will have the lowest.

Ulcerative Colitis (UC) is an inflammatory bowel disease (IBD) characterized by long-lasting inflammation and ulcers (sores) in the lining of the colon. Ulcerative Colitis (UC) commonly affects teenagers and young adults, and can result in poor development and growth; however, the disease can also occur in children and older individuals. Unlike Crohn’s disease (CD), another form of IBD that has similar symptoms to Ulcerative Colitis (UC) but can occur anywhere in the digestive tract and features ulceration deep into the tissues, Ulcerative Colitis (UC) is limited to the colon and has less frequent complications.

In the 7MM, the diagnosed prevalent cases of Ulcerative Colitis (UC) are expected to increase from 1,737,130 cases in 2016 to 1,867,305 cases in 2026, at an AGR of 0.75%. The US will have the highest number of diagnosed prevalent cases of Ulcerative Colitis (UC) over the forecast period, while Spain will have the lowest.

The report "Ulcerative Colitis: Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and temporal trends for Ulcerative Colitis (UC) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases, diagnosed prevalent cases, undiagnosed prevalent cases, and total prevalent cases of Ulcerative Colitis (UC) segmented by sex and age (starting at ages 0-9 years and ending at ages 80 years and older) in these markets.

Additionally, autoimmune comorbidities, colectomy due to failure of medical management, and mortality due to complications of Ulcerative Colitis (UC) among the diagnosed prevalent cases of Ulcerative Colitis (UC) are also included in this analysis. Furthermore, the report includes diagnosed incident cases and diagnosed prevalent cases of indeterminate colitis (IC) for both sexes and all ages in the 7MM.

Scope
  • The Ulcerative Colitis (UC) Epidemiology Forecast Report provides an overview of the risk factors and global trends of UC in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the diagnosed incident cases, diagnosed prevalent cases, undiagnosed prevalent cases, and total prevalent cases (both diagnosed and undiagnosed) of UC, segmented by sex and age (starting at ages 0-9 years and ending at ages 80 years and older) in these markets. The diagnosed incident cases are further segmented by stage at diagnosis and severity grading. The diagnosed prevalent cases are further segmented by severity grading. Additionally, autoimmune comorbidities, colectomy due to failure of medical management, and mortality due to complications of UC among the diagnosed prevalent cases of UC are also included in this analysis. Furthermore, the report includes diagnosed incident cases and diagnosed prevalent cases of indeterminate colitis (IC) for both sexes and all ages in the 7MM.
  • The Ulcerative Colitis epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The Ulcerative Colitis (UC) Epidemiology Forecast report will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global UC market.
  • Quantify patient populations in the global UC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for UC therapeutics in each of the markets covered.
  • Understand magnitude of UC population by severity, stage at diagnosis, comorbidities, and other clinically relevant segmentations.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents

2 Ulcerative Colitis: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for UC (2016-2026)
3.5.1 Diagnosed Incident Cases of UC
3.5.2 Age-Specific Incident Cases of UC
3.5.3 Sex-Specific Incident Cases of UC
3.5.4 Diagnosed Incident Cases of UC by Stage at Diagnosis
3.5.5 Diagnosed Incident Cases of UC by Severity
3.5.6 Diagnosed Prevalent Cases of UC
3.5.7 Age-Specific Diagnosed Prevalent Cases of UC
3.5.8 Sex-Specific Diagnosed Prevalent Cases of UC
3.5.9 Diagnosed Prevalent Cases of UC by Severity
3.5.10 Mortality Due to Complications Among the Diagnosed Prevalent Cases of UC
3.5.11 Colectomy Due to Failure of Medical Management Among the Diagnosed Prevalent Cases of UC
3.5.12 Comorbidities of UC Among the Diagnosed Prevalent Cases of UC
3.5.13 Undiagnosed Prevalent Cases of UC
3.5.14 Total Prevalent Cases of UC
3.5.15 Diagnosed Incident Cases of IC
3.5.16 Diagnosed Prevalent Cases of IC
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis

4 Appendix
4.1 Bibliography
4.2 Primary Research - KOLs Interviewed for this Report
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About
4.5 Contact
4.6 Disclaimer

List of Tables
Table 1: Risk Factors and Comorbidities for UC and IBD

List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of UC, Both Sexes, All Ages, N, 2016 and 2026
Figure 2: 7MM, Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016 and 2026
Figure 3: 7MM, Age-Standardized Diagnosed Incidence of UC (Cases per 100,000 Population), All Ages, Both Sexes, N, 2016
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of UC (%), All Ages, Both Sexes, N, 2016
Figure 5: 7MM, Sources Used, Diagnosed Incident Cases of UC
Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of UC
Figure 7: 7MM, Sources Used, Undiagnosed Prevalent Cases of UC
Figure 8: 7MM, Sources Used, Total Prevalent Cases of UC
Figure 9: 7MM, Sources Used, Diagnosed Incident Cases of UC by Stage at Diagnosis
Figure 10: 7MM, Sources Used, Diagnosed Incident Cases of UC by Severity
Figure 11: 7MM, Sources Used, Diagnosed Prevalent Cases of UC by Severity
Figure 12: 7MM, Sources Used, Mortality Due to CRC and TMC Among the Diagnosed Prevalent Cases of UC
Figure 13: 7MM, Sources Used, UC Cases Requiring Colectomy Among the Diagnosed Prevalent Cases of UC Due to Failure of Medical Management
Figure 14: 7MM, Sources Used, Diagnosed Incident Cases of IC
Figure 15: 7MM, Sources Used, Diagnosed Prevalent Cases of IC
Figure 16: Diagnosed Incident Cases of UC, 7MM, Men and Women, All Ages, 2016
Figure 17: 7MM, Age-Specific Diagnosed Incident Cases of UC, Both Sexes, N, 2016
Figure 18: 7MM, Sex-Specific Diagnosed Incident Cases of UC, All Ages, N, 2016
Figure 19: 7MM, Diagnosed Incident Cases of UC Segmented by Stage at Diagnosis, Both Sexes, All Ages, N, 2016
Figure 20: 7MM, Diagnosed Incident Cases of UC Segmented by Severity, Both Sexes, All ages, N, 2016
Figure 21: Diagnosed Prevalent Cases of UC, 7MM, Men and Women, All Ages, 2016
Figure 22: 7MM, Age-Specific Diagnosed Prevalent Cases of UC, Both Sexes, N, 2016
Figure 23: 7MM, Sex-Specific Diagnosed Prevalent Cases of UC, All Ages, N, 2016
Figure 24: 7MM, Diagnosed Prevalent Cases of UC by Severity, Both Sexes, =18 Years, N, 2016
Figure 25: 7MM, Mortality Due to Complications Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016
Figure 26: 7MM, Colectomy Due to Failure of Medical Management Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016
Figure 27: 7MM, Comorbidities Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016
Figure 28: Undiagnosed Prevalent Cases of UC, 7MM, Men and Women, All Ages, 2016
Figure 29: Total Prevalent Cases of UC, 7MM, Men and Women, All Ages, 2016
Figure 30: Diagnosed Incident Cases of IC, 7MM, Men and Women, All Ages, 2016
Figure 31: Diagnosed Prevalent Cases of IC, 7MM, Men and Women, All Ages, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll